• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

by MM360 Staff | Nov 25, 2025 | Uncategorized

Source: CURE articles Post Content Read More

New ‘powerful’ lab test will help researchers explore blood cancer

by Marisa Wexler, MS | Nov 24, 2025 | Myeloma News

Mission Bio has debuted a new laboratory test that enables researchers to simultaneously detect alterations in the genetic code and changes in genetic activity — starting with whether a gene is turned on or off — within the same cell. The test, dubbed the Tapestri...

Assessing the correlation between patient and family reported outcome measures and multiple myeloma clinical parameters

by MM360 Staff | Nov 24, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance

by MM360 Staff | Nov 22, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Case: Growth on pancreas shows estrogen link to pancreatic cancer

by Marisa Wexler, MS | Nov 21, 2025 | Myeloma News

Changes in how cells respond to the hormone estrogen may underlie the development of certain forms of pancreatic cancer. That’s according to findings from testing done on a growth removed from the pancreas of a woman in Japan who had given birth several months before....
« Older Entries
Next Entries »

Recent Content

  • Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis
  • (no title)
  • (no title)
  • (no title)
  • Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma
  • Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis
  • (no title)
  • Measurable residual disease assessment in multiple myeloma
  • Oncolytics to test immunotherapy against aggressive pancreatic cancer
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT